Trial · NCT07371923
Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
NCT07371923, Phase 2, Recruiting, Beijing Tongren Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma. Trials, record NCT07371923. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07371923
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
- NCT number
- NCT07371923
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Beijing Tongren Hospital
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL)
- Interventions
- Zanubrutinib+Pola-R-CHP
- First posted
- 2026-01-28
- Last updated
- 2026-01-28
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Best complete remission rate (CRR) | From the start of the first cycle of treatment up to 24 weeks (when all six cycles of treatment was completed) | Response assessment was done after every two cycles of treatment. Best CRR was defined as the CRR during all the six cycles of treatment. |
| Secondary | best overall response rate (ORR) | From the start of the first cycle of treatment up to 24 weeks (when all six cycles of treatment was completed). | Response assessment was done after every two cycles of treatment. Best ORR was defined as the ORR during all the six cycles of treatment. |
| Secondary | Two-year progression free survival (PFS) rate | From the start of the first cycle of treatment up to 24 months after initiation of treatment for the last enrolled patient. | PFS was caculated from the date of start of treatment to date of disease progression, death of any cause, or last follow-up, whichever came first. |
| Secondary | Two-year overall survival (OS) rate | From the start of the first cycle of treatment up to 24 months after initiation of treatment for the last enrolled patient. | OS was caculated from the date of start of treatment to date of death of any cause, or last follow-up, whichever came first. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07371923
GET https://conductscience.org/api/trials/v1/NCT07371923/registered